Page 59 - MEMORIA_SEHH-FEHH_2023

MEMORIA ANUAL 2023
SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
GESMD
FUNDACIÓN ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
Ensayos clínicos
Activos sin reclutamiento
• A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination
With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodys-
plastic Syndromes. Fase I. Hospital General Universitario Gregorio Marañón, Hospital
Universitario de Salamanca, ICO Badalona-Hospital Universitari Germans Trias i Pujol. Sin
reclutamiento.
• CMBG453B12301: Randomized, Double-blind, Placebo-controlled Phase III Multi-
center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With
Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R,
or Chronic Myelomonocytic Leukemia-2 (CMML-2). Fase III. Hospital Universitari i Poli-
tècnic La Fe, Complejo Asistencial Universitario de Salamanca, Hospital Universitari Vall
d’Hebron, ICO Badalona-Hospital Germans Trias i Pujol, Hospital Universitario Central de
Asturias. Finalizado el reclutamiento.
• ACE-536-MDS-002: A Phase 3, Open-label, Randomized Study to Compare the Effica-
cy and Safety of Luspatercept (ACE-536) Versus Epoetin Alpha for the Treatment of Ane-
mia Due to IPSS-R Very Low, Low or Intermediate Risk Due to Myelodysplastic Syndrome
(MDS) ESA in Native Subjects Who Require Red Blood Cell Transfusions. Fase III. Hospital
Universitari Vall d’Hebron, Hospital Universitario 12 de Octubre, Hospital Universitario
Virgen de las Nieves, Hospital General Universitario Gregorio Marañón, Hospital Clínico
Universitario de Valencia, Hospital Universitari i Politècnic La Fe, Hospital Universitario de
Salamanca, ICO L’Hospitalet-Hospital Duran i Reynals, Hospital Universitario Central de
Asturias. Finalizado el reclutamiento.
• A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological
Malignancies With Isocitrate Dehydrogenase (IDH) Mutations. Fase I. Hospital Clínico
Universitario de Valencia, ICO L’Hospitalet-Hospital Duran i Reynals, Clínica Universidad
de Navarra, Hospital Universitario 12 de Octubre. En reclutamiento.
• A Phase 1, FIH, Dose Escalation Study of JNJ-74856665 (Dihydroorotate Dehydro-
genase [DHODH] Inhibitor) Alone or in Combination in Participants With AML or MDS.
Fase I. Hospital Clínic de Barcelona, Hospital Universitario Vall d’Hebron, ICO L’Hospitalet-
Hospital Duran i Reynals, Clínica Universidad de Navarra, Hospital Universitario Funda-
ción Jiménez Díaz. Activo sin reclutamiento.
59